⚠
Is this information incorrect? This profile was AI-generated from publicly available sources and may contain errors. If you are a representative of NMD Pharma A/S and believe any information on this page is inaccurate, we will promptly correct or remove it.REPORT AN ERROR
NMD Pharma A/S
↗Aarhus, Denmark
NMD Pharma is a clinical-stage biotechnology company dedicated to developing novel, first-in-class small molecule therapies that selectively target the skeletal muscle chloride ion channel (ClC-1). By inhibiting ClC-1, the company's platform aims to amplify muscle responsiveness to weak signals, thereby restoring neuromuscular transmission and skeletal muscle function in patients suffering from severe neuromuscular disorders.
Founded in 2015 as a spin-out from Aarhus University, Denmark, the company leverages over 15 years of research into muscle physiology and electrophysiology. NMD Pharma is currently advancing a pipeline of candidates, with its lead program, NMD670, being evaluated in multiple clinical trials for conditions such as myasthenia gravis, spinal muscular atrophy, and Charcot-Marie-Tooth disease.
CLASSIFICATION
SIZE & FINANCIALS
Employees:51-200
Founded:2015
Ownership:private
Status:operating
FUNDING
Stage:Late-stage venture
Total Raised:$180M
Investors:Novo Holdings, Lundbeckfonden BioCapital, INKEF Capital, Roche Venture Fund, Jeito Capital
PIPELINE
Stage:Phase 2
Lead Drug Stage:Phase 2
Modalities:Small molecule
Active Trials:3
Trial Phases:Phase 2: 3
FDA Approvals:0
EMA Approvals:0
CORPORATE STRUCTURE
Key Partnerships:Aarhus University (Academic origin/collaboration)
COMPETITION
Position:Emerging
LEADERSHIP
Key Executives:
Thomas Holm Pedersen - CEO
Thomas Kongstad Petersen - COO
Dan Brennan - SVP Corporate and Commercial Strategy
Scientific Founders:Thomas Holm Pedersen
LINKS
Website:nmdpharma.com
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with NMD Pharma A/S. The information on this page was compiled using AI from publicly available sources and may be incomplete, outdated, or contain errors. We are committed to correcting inaccuracies promptly upon notice. For official information, please visit the company's website directly.